Amylin the Hormone

Insulin and amylin are partner hormones. In patients with diabetes, secretion of both may be deficient

Amylin is a naturally occurring neuroendocrine hormone synthesized by pancreatic beta cells that contributes to glucose control during the postprandial period.1-3

Mean 24-hour secretion profile of amylin and insulin in healthy adults (n = 6)1,4

Mean 24-hour secretion profile of amylin and insulin in healthy adults (n = 6) Mean 24-hour secretion profile of amylin and insulin in healthy adults (n = 6) Mean 24-hour secretion profile of amylin and insulin in healthy adults (n = 6)
  • Both hormones are secreted by pancreatic beta cells
  • Both are secreted in response to food intake

Mean secretion profile of amylin in adult patients with diabetes4

Mean secretion profile of amylin in adult patients with diabetesMean secretion profile of amylin in adult patients with diabetesMean secretion profile of amylin in adult patients with diabetes
  • In patients with type 1 and type 2 diabetes, there is reduced secretion from pancreatic beta cells of both insulin and amylin in response to food
  • Insulin and amylin may need to be replaced
 

Mechanism of Action

Amylin contributes to postprandial glucose regulation through 3 mechanisms1

Amylin contributes to postprandial glucose control through 3 mechanismsAmylin contributes to postprandial glucose control through 3 mechanisms

WARNING: SEVERE HYPOGLYCEMIA
SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours following a SYMLIN injection. Serious injuries may occur if severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. Appropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk.

 

Pharmacodynamic Effects of SYMLIN

SYMLIN reduced postprandial glucose levels when administered prior to meals with mealtime insulin1,5,6

A randomized, single-blind, placebo-controlled, 5-way crossover pharmacodynamic study evaluated the effect of pramlintide in combination with insulin lispro or regular insulin on postprandial glucose concentrations in adult patients with type 15 or type 26 diabetes who underwent a standardized mixed meal test for 5 consecutive days.

Regular insulin: type 1 patients1,5

Regular insulin: type 1 patients Regular insulin: type 1 patients Regular insulin: type 1 patients

Lispro insulin: type 1 patients1,5

Lispro insulin: type 1 patients Lispro insulin: type 1 patients Lispro insulin: type 1 patients

Lispro insulin: type 2 patients1,6

Lispro insulin: type 2 patients Lispro insulin: type 2 patients Lispro insulin: type 2 patients